Clinical Trial

Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes

Study acronym: AID-DM
Recruiting
View on ClinicalTrials.gov →
Summary
A national multi-center open-label randomized controlled trial that investigates whether the use of the automated insulin delivery system CamAPS FX initiated during pregnancy planning or in early pregnancy improves maternal time in glycemic targets and fetal growth in women with type 1 diabetes compared to usual insulin treatment modality combined with Continuous Glucose Monitoring.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-16; most recent amendment 2026-01-13.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07240012
Lead Sponsor Rigshospitalet, Denmark
Collaborators: The Novo Nordic Foundation, mylife Diabetes Care AG, Abbott
Conditions Diabete Type 1, Pregnancy Complications
Enrollment 305 participants
Start Date 2025-12-01
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-12